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ABSTRACT 
Under pathological conditions, microglia, the resident CNS immune cells, 
become reactive and release pro-inflammatory cytokines and neurotoxic 
factors. We investigated whether this phenotypic switch includes changes in the 
expression of the L-type voltage-gated calcium channel (VGCC) in a rat model 
of N-methyl-D-Aspartate-induced hippocampal neurodegeneration. Double 
immunohistochemistry and confocal microscopy evidenced that activated 
microglia express the L-type VGCC. We then analyzed whether BV2 microglia 
express functional L-type VGCC, and investigated the latter’s role in microglial 
cytokine release and phagocytic capacity. Activated BV2 microglia express the 
CaV1.2 and CaV1.3 subunits of the L-type VGCC determined by reverse 
transcription-polymerase chain reaction, Western blot and 
immunocytochemistry. Depolarization with KCl induced a Ca2+ entry facilitated 
by Bay k8644 and partially blocked with nifedipine, which also reduced TNF-α 
and NO release by 40%. However, no nifedipine effect on BV2 microglia 
viability or phagocytic capacity was observed. Our results suggest that in CNS 
inflammatory processes, the L-type VGCC plays a specific role in the control of 
microglial secretory activity. 
 
KEYWORDS: L-type voltage-gated calcium channel, excitotoxicity, 
dihydropyridine receptor, neuroinflammation, neurodegeneration. 
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Introduction 
Microglial reaction is an early event which often precedes and triggers neuronal 
death in CNS pathological situations such as Alzheimer’s and Parkinson’s 
diseases, amyotrophic lateral sclerosis, multiple sclerosis, ischemia and brain 
trauma (Graeber and Streit, 2010). As a response to signals released during 
injury, this microglial transition from a surveillance state towards a more reactive 
one represents an important phenotypic change (Colton and Wilcock, 2010; 
Domercq et al., 2013; Kettenmann et al., 2011). As a result, reactive microglia 
releases pro-inflammatory cytokines and neurotoxic factors, such as tumor 
necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and reactive oxygen species, 
the excessive production of which may trigger or exacerbate neuronal death 
(Liao et al., 2012; Zhang et al., 2011). In addition, some microglial cells become 
increasingly dysfunctional as they age, and may participate directly in the 
development of secondary tissue injury and neurodegeneration (Damani et al., 
2011; Liao et al., 2012). Therefore, control of microglial activation should bring 
therapeutic benefit for any central disorder related with neuroinflammation. A 
growing body of evidence suggests that ion channels expressed by microglia 
are modulators of cell functions, and highlights their direct involvement in these 
neuropathologies (Kettenmann et al., 2011; Ortega et al., 2012a, 2013; 
Rodríguez et al., 2013; Virgili et al., 2011, 2014).  
Electrophysiological studies suggest that microglia express a voltage-gated 
calcium channel (VGCC) which mediates Ca2+ entry (Colton et al., 1994; Hegg 
et al., 2000; Silei et al., 1999). Structurally, all VGCC family members are 
organized as heteromeric complexes of five subunits: α1, α2, β, δ, and γ 
(Zamponi and Snutch, 2013). The α1 subunit is the pore-forming component 
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and functions as the voltage sensor (Catterall et al., 2005). The heterogeneity of 
each subunit gives rise to different VGCC pharmacological and 
electrophysiological properties and to the classification of the P-, Q-, N-, L-, R-, 
and T-type channels (Catterall et al., 2005). The α1C (CaV1.2) and α1D (CaV1.3) 
genes encode the α1 subunit of the L-type Ca2+ channel, which was first 
recognized as essential for coupling excitation to contraction in skeletal, 
cardiac, and smooth muscle cells (Lipscombe et al., 2004). The L-type VGCC is 
also expressed in neurons and endocrine cells where it regulates a diversity of 
processes including neurohormone and transmitter secretion, gene expression, 
mRNA stability, synaptic efficacy, and the activity of other ion channels 
(Ashcroft et al., 1994; Bading et al., 1993; Bean, 1989). 
The L-type VGCC, which has a role in neuronal survival and ischemia-induced 
axonal injury, is considered a target for therapies designed to interfere with 
neuropathological processes. Thus, L-type VGCC blockade with dihydropyridine 
or nimodipine reduces neuronal damage and improves behavioral outcome 
accompanied with excitotoxicity, traumatic brain injury and ischemia (Bernal et 
al., 2009; Mattsson et al., 1999; Zhu et al., 1999;). However, calcium antagonist 
treatments in hypoxia-ischemia models have an effectiveness of only 50% 
(Horn et al., 2001) and these same VGCC blockers present contradictory 
results in a large number of calcium-mediated excitotoxic processes (Berg et 
al., 1995; Bernal et al., 2009; Frandsen et al., 1993; Fryer et al., 1999; Horn et 
al., 2001; Petegnief et al., 2004; Rami and Krieglstein, 1994; Small et al., 1997). 
Inside this framework, the characterization of microglial expression of the L-
typeVGCC after brain injury will help to establish why the channel blockade 
therapy remains so challenging in experimental and clinical assays. 
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In this paper we postulated that phenotypic activation of microglia during injury 
alters L-type VGCC expression, resulting in a modification of intracellular 
microglial events such as cytokine release and phagocytosis. We investigated 
activated microglia in our in vivo experimental model of neurodegeneration and 
in in vitro cultures of the BV2 microglial cell line. In our rodent model, N-methyl-
D-aspartate (NMDA) is stereotaxicaly microinjected into the hippocampal 
formation to induce a neurodegenerative process involving neuronal necrosis 
and a potent inflammatory reaction mainly mediated by microglia (Ortega et al., 
2012b; Rodríguez et al., 2013). BV2 cell culture allows the determination of the 
function of the L-type VGCC in microglia activity. Our results suggest a major 
role for the L-type VGCC in specifically controlling microglial pro-inflammatory 
activity in CNS pathologies. 
Material and methods 
Animals 
Adult male Wistar rats (body weight 200-225 g at the beginning of the study) 
were obtained from the animal housing facilities of the School of Medicine at the 
University of Barcelona). They were kept on a 12 hours/12 hours day and night 
cycle, and housed with free access to food and water. Animals were handled in 
accordance with European legislation (86/609/EEC). All efforts were made to 
minimize the number of animals used and their suffering. The procedures were 
approved by the University of Barcelona’s Ethics Committee under the 
supervision of the Catalan government. 
Materials 
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Murine BV2 microglial cell line was purchased from Cell Bank (Interlab Cell Line 
Collection, ICLC, Geneva, Italy). RPMI medium supplemented with L-glutamine 
was purchased from GIBCO (USA). Fetal Bovine Serum, was from VWR 
Scientific (San Francisco, USA). All culture plaques and flasks were purchased 
from Nunc (Roskilde, Denmark). N-Methyl-D-Aspartate, lipopolysaccharide from 
Escherichia coli 026:B6 (LPS), interferon-gamma (IFNγ), Nifedipine, nimodipine, 
Bay k8644, the biotin-conjugated isolectin B4 (IB4) from Bandeiraea simplifolia, 
the mouse monoclonal anti-Glial fibrillary acidic protein (GFAP) antibody, 
peroxidase-conjugated IgG as secondary antibody, and the Extradivin-Cy3 
conjugate were all from Sigma-Aldrich (St. Louis, CA). The polyclonal rabbit 
anti-α1C antibody was from Alomone Labs (Jerusalem, Israel). Goat anti-rabbit 
IgG antibody conjugated with Alexa-fluor 488, Goat anti-mouse IgG antibody 
conjugated with Alexa-fluor 555 and FluoSpheres Carboxylate-modified 
microspheres were from Invitrogen (Carlsbad, CA). The fura-2 acetoxymethyl 
ester was from Calbiochem (San Diego, CA).  
Stereotaxic procedure and rat brain sample collection  
Under equithesin anesthesia (a mixture of chloral hydrate and sodium 
pentobarbital; 0.3 ml/100g body wt., i.p.) eight rats were placed in a stereotaxic 
instrument (David Kopf, Carnegie Medicine, Sweden) with the incisor bar set at 
-3.3 mm. Following Paxinos and Watson’s Atlas (Paxinos and Watson, 1986), 
the stereotaxic coordinates of the hippocampal microinjection were 3.3 mm 
caudal to bregma, 2.2 mm lateral to bregma and 2.9 mm ventral from dura. A 
5.0 µl Hamilton syringe activated by an infusion pump (CMA/100; Carnegie 
Medicine, Sweden) was used for the intracerebral injection into the hippocampal 
parenchyma. All injections lasted 5 min. After onset of the infusion of 0.5 µl, the 
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needle was left in place for an additional 5 min to allow passive diffusion and to 
prevent spread of the excitotoxin up the cannula track upon removal; then, the 
needle was slowly retracted. Four animals received a single microinjection of 20 
nmol NMDA in 50mM phosphate buffer saline (PBS; pH 7.4) (NMDA group n 
=4) or a single microinjection of 50mM PBS (pH 7.4) (sham group n = 4). 
On day 15 post-lesion, rats were anaesthetized with equithesin and 
transcardially perfused with 300 ml of 0.01 M PBS followed by 300 ml of 4% 
(w/v) paraformaldehyde in 0.01 M PBS. Brains were then removed, post-fixed 
for 2 hours, and thereafter transferred to 15% (w/v) sucrose in PBS at 4ºC for 
three days. The brains were frozen with powdered dry ice and stored at -80ºC 
until use. Coronal serial 14 µm sections at the level of the injection site (3.3 mm 
caudal to bregma) were obtained and mounted on slices pretreated with poly-L-
lysine (10% w/v in distilled water). 
Histology, immunohistochemistry and confocal analysis 
Standard Nissl staining of brain slices was performed to evaluate neuronal loss 
and the morphology of the hippocampal region. Microglial cells were identified 
by histochemistry with biotin-conjugated IB4 (Rodríguez et al., 2001). Briefly, 
sections were incubated overnight at 4 ºC with IB4 diluted 1:25 in normal goat 
serum (NGS, 1:100 v/v in 0.01 M PBS; pH 7.4). Immunohistochemistry was 
carried out in consecutive sections with the avidin-biotin peroxidase method as 
previously described (Rodríguez et al., 2009a). The L-type VGCC was labeled 
with polyclonal rabbit anti-α1C antibody (1/200) in 3% NGS. After incubation with 
ExtrAvidin (1/250), sections were developed in a 0.05 M Tris solution containing 
0.03% (w/v) diaminobenzidine (DAB) and 0.006% (v/v) H2O2. Finally, sections 
were dehydrated, cleared and mounted with DPX.  
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The hippocampal size and the area occupied by the neural loss were measured 
on Nissl stained sections using a computer-assisted image analysis system 
(Image-Pro Plus, Media Cybernetics Inc., MD, USA). Microglial reaction area 
was measured on IB4-stained sections using the same system. In both cases, 
the area of contralateral hippocampus was measured in the same sections in 
order to estimate the effects of histological procedures on tissue size, and thus 
to correct for variability in individual bain size and tissue shrinkage. 
Stereological counting was made on sections from NeuN single immunostaining 
or IB4 histochemistry. We applied the optical fractionator method to count 
labeled cells (Ortega et al., 2013). Lesioned regions of the hippocampal 
formation were outlined at 2.5x magnification on arbitrary uniform random 
(AUR) coronal sections. Individual cells were viewed at 40x in AUR-sampled 
sites chosen by the Mercator Pro 7.0 software (ExploraNova) and then counted. 
To determine the presence of L-type VGCC in microglia, double 
immunohistochemistry was performed with the polyclonal rabbit anti-α1C 
antibody and IB4 (1/25) as a specific markers for microglia. 14 µm-thick 
adjacent sections were first incubated for 2 hours at room temperature in PBS 
containing 0.1% Triton X-100, 5% BSA and 5% NGS. Then, sections were co-
incubated overnight at 4ºC with the anti-α1C antibody (1/200) and the IB4 
(1/25). Antibodies against the IgG of appropriate species, conjugated with 
fluorescent dyes Alexa-fluor 488 (1/300) or Alexa-fluor 555 (1/300) Extravidin-
Cy3 conjugate (1/500), were used to detect microglial cells. All sections were 
mounted in Pro-long antifade and kept in the dark. Incubations with either 
mouse or rabbit IgG as primary antibodies were used for negative controls. In 
each 14 µm-thick slice, series of 10 confocal images were acquired at x40 using 
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a Leica TCS SL laser scanning confocal spectral microscope (Z resolution = 
586 nm; Leica Microsystems Heidelberg GmbH, Mannheim, Germany). Co-
localization of fluorescent labelling in the hippocampus was analyzed in single 
confocal images by displaying the spatial distribution of normalized mean 
deviation product (MDP) values with an appropriate lookup table (Jaskolski et 
al., 2005) and by displaying the scatter plot of pixel distribution of each image. 
The co-localization study was performed as published elsewhere (Manders et 
al., 1993)  and included the estimation of Pearson’s r that describes the extent 
of overlap between image pairs and gives a value between -1 and 1, with -1 
being no overlap whatsoever between images and 1 a perfect image 
registration. The Overlap coefficient R, which describes overlap independently 
from intensity image, and Overlap coeficients for green (k1) and red (k2) where 
also calculated. All image analyses were made with ImageJ 1.39u (National 
Institutes of Health, USA) and FluoColoc (ExploraNova, France) specific 
software. The number of cells showing double immunostaining was estimated 
by counting of cells on 3 random confocal photomicrographs (n = 60 
cells/image). Results are given as a percentage of the total number of cells. 
BV2 cell culture, immunocytochemistry and phagocytic assay 
BV2 cells were cultured in RPMI 1640 medium with L-glutamine and 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 
100U/ml penicillin and 100 µg/ml streptomycin. Cells were grown in a humidifier 
cell incubator containing 5% CO2 at 37ºC. Before activation, cells were sub-
cultured on 24-well plates at a density of 5x104 cells/ml for 24 hours, and plates 
were divided into 5 groups of cultured cells: a) One group with no further 
manipulation, called control; b) The C+Nif group, in which BV2 cells were 
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incubated with 10 µM Nifedipine 24h after sub-culture; c) the L+I group, in which 
BV2 cells were activated with lipopolysaccharide (LPS)+ interferon gamma 
(IFNγ) (0.1 µg/ml and 0.5 ng/ml) for 48 hours as described elsewhere (Ortega et 
al., 2012a), d) the L+I+Nif group, in which cells were incubated with 10 µM 
Nifedipine 24h after activation with LPS+ IFNγ and e) the L+I+Bayk group, in 
which cells were incubated with 10 µM Bay k8644 24h after activation with 
LPS+ IFNγ. 10µM Nifedipine was used for spacific pharmacological blockade of 
the L-type VGCC and 10µM Bay k8644 for specific openning of the channel. In 
some experiments, 25 µM Nimodipine was used to block L-type VGCC. 48 
Forty-eight hours after activation, culture media were collected for further 
analysis and protein and mRNA purification was performed using the 
NucleoSpin® RNA/Protein kit (QUIAGEN, Düsseldorf, Germany) in accordance 
with the manufacturer’s specifications.  
For immunocytochemistry assays, BV2 cells were grown on poly-D-lysine-
coated sterile coverslips and the medium was changed on the day of activation 
with LPS+IFNγ. At 48 hours, cells were fixed in ice-cold methanol for 8 minutes. 
Immunodetection was performed using anti- α1C (1/1000) primary antibody 
detected with Alexa-fluor 488 conjugated secondary antibody (1/500). Controls 
for non-specific binding were performed, excluding primary antibodies. Cell 
nuclei were stained with Hoechst33258 (2.5µg/ml in PBS). Coverslips were 
mounted with Pro-long Antifade and slices were stored at 4ºC. Images were 
acquired using a Zeiss Axio Observer Fluorescence Microscope (Göttingen, 
Germany). 
For the study of the phagocytic capacity, cells were incubated for 30 minutes at 
37ºC in the presence of 2µm diameter FluoroSpheres at 0.01% solid mass as 
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described previously by Ortega et al. (2012a). In parallel, immunofluorescence 
with anti-alpha-tubulin antibody conjugated with FITC was carried out for cell 
identification, as described above. Five images/well were acquired randomly 
using Zeiss Axio Observer Fluorescence Microscopy. Quantification was done 
in each picture with ImageJ, by counting the cells containing at least one 
fluorosphere. 
Measurement of cytosolic-free Ca2+ and stimulation of VGCC 
Intracellular calcium concentration ([Ca2+]i) was measured as described in detail 
previously (Bataller et al., 2001; Soto et al., 2004). Briefly, BV2 cells were plated 
on 25-mm diameter glass coverslips (VWR Scientific Inc., Philadelphia, PA) and 
then loaded with 4 µM fura-2/acetoxymethyl ester (Calbiochem, San Diego, CA) 
for 35 minutes at 37°C in an incubation buffer of 130 mM NaCl, 10 mM HEPES, 
2.7 mM KCl, 1.2 mM 1.2 MgCl2, 2.5 mM CaCl2 and 10 mM glucose at pH 7.4 
with NaOH. Fura-2-loaded BV2 microglia were then transferred into an open 
flow chamber mounted on the heated stage of an inverted epifluorescence 
microscope (Diaphot-300; Nikon, Tokyo, Japan) and maintained at 37°C. 
Examination of the fura-2 fluorescence distribution did not show significant 
intracellular heterogeneity. Fluorescence images were obtained at 40x by a 
charge-coupled device camera (CH250; Photometrics, Tucson, AZ) digitized, 
stored, and analyzed on a computer (Macintosh 840AV; Apple, Inc., Cupertino, 
CA). After a stabilization period of 10 min, image pairs were obtained alternately 
every 4 seconds, and, for a total of 12 minutes, at excitation wavelengths of 340 
and 380 nm (10-nm bandwidth filters), to excite the Ca2+-bound and Ca2+-free 
forms of this ratiometric dye respectively. The emission wavelength was 510 nm 
(120-nm bandwidth filter) and [Ca2+]i values were calculated on a single cell 
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basis by determining the 340- to 380-nm fluorescence (F340/F380) ratios at each 
time point. All images were checked for movement artifacts, and a reference 
point was used to obtain true co-registration of the 340-nm and 380-nm images.  
The opening of the VGCC was induced through cell membrane depolarization 
by addition of 80 mM KCl as previously described (Bataller et al., 2001). 
Osmolarity effects were controlled for using 50 to 150 mM NaCl. KCl addition 
was not associated with any change in cell viability, as assessed by trypan blue 
exclusion assay (Strober, 2001). Pharmacological blockade of the VGCC was 
performed by addition of 10µM Nifedipine to the incubation medium, and 
openning of the channel was induced by addition of 10µM Bay k8644 to the 
incubation medium. Cells were considered to be responders when [Ca2+]i 
increased by more than 20% relative to the baseline level. Each condition was 
analized in cells from 3-7 different cultures.  
RT-PCR analysis and Western blotting of CaV1.2 and CaV1.3 in BV2 cells 
RT-PCR was performed to assess the presence of α1C mRNA inside BV2 cells. 
Total RNA from BV2 cells was isolated using NucleoSpin RNA/protein kit in 
accordance with the manufacturer’s instructions (Macherey-Nagel, Germany). 
The concentration of total RNA isolated was quantified using a NanoDrop 
N1000 spectrophotometer (Thermo, Wilington, DE). Specific primers were 
designed against mouse mRNA sequences of the subunits α1C and α1D of the 
L-type VGCC as described previously (Toba et al., 2005). The sequences for 
α1C are: F 5’-TGCCTGGTGCTCGGGGTTTC-3’; R 5’-
GGGGGTGGACCGCACCATTT-3’ (GeneBank accession number: 
NM_009781). The sequences for α1D are: F 5’-
GCACCGTGGTGTCCTGTGAATGC-3’; R 5’- 
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GGAAAGTGATGGGATGAGATCTC-3’ (GeneBank accession number: 
AK018426). Sequence of 18S non-coding mRNA (GeneBank accession 
number: NR_003278.1) was used as control. RT reactions were carried out 
using random primers and 2 µg of mRNA as described by the manufacturer with 
AffinityScript Multiple Temperature cDNA Synthesis kit (Stratagene, CA). PCR 
was performed with the Taq PCR Core kit of Qiagen (Studio City, CA) using 2µl 
of RT reaction as a template. The cycling conditions were those described 
previously (Toba et al., 2005). For 18S mRNA, cycling conditions complied with 
the manufacturer’s instructions, with the annealing temperature fixed at 57ºC. 
Appropriate templates were included as positive and negative controls. PCR 
products (10 µl) were separated by 1.5% agarose gel electrophoresis and 
visualized by staining with ethidium bromide.  
Whole cell culture proteins and brain homogenates were obtained in RIPA 
buffer (Santa Cruz Biotechnology, Santa Cruz, CA) as described previously 
(Ortega et al., 2012a). The supernatant and the pellet were collected. Aliquots 
containing 20 µg protein were subjected to 10% SDS-PAGE. Proteins were 
transferred to Nitrocellulose membrane (Amersham Pharmacia Biotech, San 
Francisco, CA) and probed by incubation with anti-α1C (1/200), as primary 
antibodies and with peroxidase-conjugated IgG (1/2500) as secondary antibody. 
Blots were visualized using the enhanced chemiluminescence system ECL-
Plus, following the manufacturer's instructions, and exposed to X-ray film 
(Amersham Pharmacia Biotech, San Francisco, CA). 
Quantification of NO and TNF-α released by BV2 microglia 
Whole cell culture proteins were obtained in RIPA buffer (Santa Cruz 
Biotechnology, Santa Cruz, CA) as described previously (Ortega et al., 2012a). 
14	  
The supernatant and the pellet were collected. NO production was assessed in 
culture supernatants by the Griess reaction, a colorimetric assay that detects 
nitrite (NO2–) as a stable reaction product of NO with molecular oxygen (Virgili et 
al., 2011) . Briefly, 50 µL of each sample was incubated with 25 µL of Griess 
reagent A (1% sulfanilamide, 5% phosphoric acid) and 25 µL of Griess reagent 
B (0.1% N-1-naphthyl oenediamine) for 5 min. The optical density of the 
samples was measured at 540 nm using a microplate reader (Sunrise-Basic 
Reader, TECAN). The nitrite concentration was determined from a sodium 
nitrite standard curve. The amount of TNF-α released in the cell culture 
supernatants was determined using an ELISA murine TNF-α kit (PeproTech; 
London, UK) following the manufacturer’s guidelines. 
Statistical analysis 
Kurtosis and Skewness moments were calculated to test the normal distribution 
of data. Variance homogeneity was checked by Cochran's C, Bartlett's, 
Hartley's, and Levene's tests. Association with continuous parameters was 
tested with one-way ANOVA followed by the Fisher’s least significant difference 
(LSD) post-hoc test. Normality of residuals was checked by quantile-quantile 
plot analysis. When normality was not reached, the non-parametric Kruskal-
Wallis (KW) test and then the Mann-Whitney U test were used to compare 
values for all groups All values are presented as mean ± standard error of the 
mean (SEM), and differences were considered to be significant at the P<0.05 
level. Data were analyzed with the statistical analysis package StatGraphics 5.0 
(STSC Inc., Rockville, MD, USA). 
Results 
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Reactive microglia express Cav1.2 channels after NMDA-induced 
hippocampal lesion. 
As described above, 20 nmol NMDA administration in the rat hippocampus 
induced a neurodegenerative process characterized at 15 days by a severe 
necrotic neuronal death and microglial reaction (Figure 1). Microscope 
observation of Nissl-stained sections revealed major NMDA-induced layer 
disorganization, neuronal loss and microgliosis in all layers of the hippocampal 
formation, including oriens, pyramidal, lacunosum-moleculare and radial strata 
of CA1, as well as in granular layers of the dentate gyrus (DG) (Figure 1A-B). 
This lesion covered an area of 3.2 ± 0.48 mm2 (55% of the whole hippocampal 
formation area, Figure 1G). Counting of NeuN-immunopositive neurons 
indicated a mean 64% neuronal loss, affecting most hippocampal subfields and 
part of dentate gyrus (Fig. 1C-D). A maximum 79 ± 4% effect was reached in 
the CA1 pyramidal layer (Figure 1H), whose neuronal density (neurons/ mm2), 
compared to the sham group, was reduced from 2154 ± 55 to 201 ± 6. In this 
hippocampal subfield, surviving neurons lost their characteristic pyramidal 
morphology and presented an abnormal shape of their soma and dendritic tree 
(detail in Figure 1C,D).  
IB4 immunohistochemistry showed abundant microglia with reactive 
morphology, hypertrophy, hyperplasia and high IB4 immunostaining distributed 
over the entire lesioned area (Figure 1E-F), which evidenced a lesion-
associated microgliosis. The area of this microgliosis reached 5.1 ± 0.97 mm2 
(87% of the whole hippocampal formation, Figure 1I). Morphology of IB4-
labeled cells changed with their location and proximity to the injection site. The 
small cell body and several ramifications of resting microglia in healthy tissue 
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(detail in Figure 1E) changed progressively into a mixed reactive-amoeboid 
morphology in the core of the lesion (detail in Figure 1F). Counting of IB4-
positive cells indicated a mean 46 ± 8% (p = 0.03) increase in the number of 
microglial cells in the lesioned hippocampus (not shown). 
In control rats, immunohistochemistry with anti-rat α1C antibody labeled the 
pyramidal CA1-CA3 cell layers of the hippocampus and the DG granular cell 
layer. Specific α1C-immunoreactivity was also evident in the dendrites of the 
stratum radiatum and, less densely, in the stratum lacunosum-moleculare of 
CA1 (Figure 1J). The intense neuronal loss and layer disorganization induced 
by NMDA microinjection modified the distribution of hippocampal staining with a 
reduction in the pyramidal CA1 and granular DG layers which almost 
disappeared in the radiatum stratum of CA1 (Figure 1K). Surviving neurons that 
still expressed α1C showed an abnormal morphology in pyramidal layers (Figure 
1K1). However, non-neuronal specific anti-rat α1C immunostaining (Figure 1K2) 
was observed homogeneously distributed in all lesioned hippocampal cell 
layers. Confocal microscopy and image analysis of double histochemistry with 
anti-α1C antibody and IB4 revealed a clear expression of Cav1.2 channels in 
most amoeboid reactive microglia of the lesioned hippocampal formation 
(Figure 2D-F,K). Image analysis revealed specific anti-α1C antibody labelling 
located at the cytoplasma and the plasma membrane of 36 ± 8% IB4 positive 
cells (Figure 2D-F) The mean values of co-localization parameters from MDP 
images were: Pearson’s r = 0.430, overlap coefficients R = 0,589, k1 = 0.712, 
and k2 0.675 (n = 6 different MDP images from 3 lesioned rats) (Figure 2G-I). 
Specific anti-α1C staining did not co-localize IB4 stainig in some reactive cells of 
the lesioned hippocampus. Co-localization of anti-α1C antibody and IB4 staining 
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was not found in the hipocampus of control rats (Pearson’s r = 0.065, R = 
0.462, k1 = 0.699, and k2 = 0.304; n = 6 different MDP images from 3 control 
rats). (Figure 2A-C, J). 
BV2 microglia express α1 subunits of L-type VGCC 
To study the functions of the L-type VGCC in microglial cells in vitro, we first 
analyzed the expression of Cav1.2 and Cav1.3 channels by RT-PCR analysis of 
total RNA extracted from three different cultures of the activated murine 
microglia-derived cell line BV2. We examined the expression of the L-type 
VGCC by analyzing distinct pore-forming α1 subunit PCR products. The PCR 
products for α1C (Cav1.2) and α1D (Cav1.3) found in the RNA preparation of BV2 
were comparable to those obtained from whole brain RNA preparations used as 
positive controls (Figure 3A-B). 
The presence of α1C protein in microglial BV2 was studied by Western blotting 
of the membrane protein extracts isolated from three different cultures of BV2 
cells. A positive signal was observed at 240 KDa (Figure 3C), indicating the 
presence of the L-type VGCC in the microglial membrane. Compared to 
quiescent cells, densitometry quantification evidenced a significant 63 ± 7% 
increase (n= 5 different cultures; p=0.0072) in the expression of α1C protein in 
BV2 cells activated with LPS and IFNγ during 24 hours. Immunofluorescence 
localized α1C in BV2 cells and complemented western blotting and PCR results 
(Figure 3D-F). Specific α1C immunoreactivity was clearly located at the plasma 
membrane and characteristic membrane processes of BV2 cells stimulated with 
LPS+IFNγ (Figure 3F), whereas non-activated BV2 cells presented a weak 
immunostaining similar to background (Figure 3E).  
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L-type VGCC specific drugs modify KCl-induced intracellular calcium 
increase in BV2 microglia 
Application of high K+ concentrations in the culture medium has classically been 
used to depolarize the cell membrane and consequently to activate voltage-
operated channels. To study whether cell membrane depolarization is able to 
produce an [Ca2+]i increase in activated microglia, control and LPS+IFNγ 
stimulated BV2 cells were loaded with the fluorescent intracellular calcium 
probe Fura-2 and monitored. We used 10 µM Nifedipine as specific L-type 
VGCC blocker and 10 µM Bay k8644 as specific openner of the channel (Figure 
4A-B).  
In control cells, the basal F340/F380 ratio was 0.223 ± 0.008 and no spontaneous 
intracellular calcium oscillations were observed in these conditions. Addition of 
10 µm nifedipine or 10 µm Bay k8644 did not modify this ratio (F340/F380 values 
were 0.203 ± 0.01 and 0.236 ± 0.02 respectively; KW = 7.671, p = 0.175) and 
no spontaneous intracellular calcium oscillations were observed in these 
conditions. Addition of 80 mM KCl to the medium increased [Ca2+]i to a F340/F380 
ratio of 0.2987 ± 0.03 in 42% of control BV2 cells (45 out of 107, from 3 different 
assays) (Figure 4C-D). In these responding cells, the mean amplitude of the 
response increased a 28.2 % the F340/F380 ratio from the baseline level (Figure 
4E), with a mean duration of 180 seconds. Trypan blue staining showed that the 
cell viability was not compromised by the calcium response to high potassium 
levels. 10 µM nifedipine decreased the F340/F380 ratio to a mean value of 0.2198 
± 0.01 and the number of control BV2 cell responding to KCl to 35.9%. Bay 
k8644 did not modified the ratio but increased the percent number of 
responding cells until 52.5% (KW = 9.955, p=0.0016) (Figure 4C, D). Both drugs 
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also modified the mean amplitude of [Ca2+]i increase in responding cells. In 
presence of nimodipine the KCl-induced F340/F380 ratio increased 23% from the 
baseline level, whereas in the presence of Bay k8644 the ratio increased 37% 
from the baseline level (KW = 8.557, p=0.0136) (Figure 4E). 
In cells stimulated with LPS+IFNγ the basal F340/F380 ratio was 0.221 ± 0.03. 
Addition of 10 µm nifedipine or 10 µm Bay k8644 did not modified this ratio 
(mean values 0.2163 ± 0.03 and 0.2461 ± 0.04 respectively, KW = 6.521, p = 
0.535). 81% of LPS+IFNγ stimulated cells (165 out of 204, from 7 different 
assays) showed an increase of [Ca2+]i to a ratio of 0.307 ± 0.03 due to 80 mM 
KCl (Figure 4C-D). In these responding cells, the mean amplitude of the 
response increased the ratio a 27.8 % from the baseline level (Figure 4E), with 
a mean duration of 180 seconds. When 10 µM nifedipine was added to 80 mM 
KCl, the response of LPS+IFNγ-stimulated cells fell significantly (Figure 4C-D). 
Only 42% of cells responded (109 out of 261 from 7 different assays), the mean 
F340/F380 ratio decreased to 0.2503 ± 0.03 (Figure 4C) (F3,250 = 90.07, p = 
0.00001), which correnponded to a 27.8 % increase from the baseline level in 
responding cells (Figure 4E). Nifedipine also changed the time to reach the 
maximal calcium concentration (Tpeack) of the response from 31.4 ± 3.34 s to 
63.1 ± 2.29 s (p< p.05), whereas the duration of the intracellular calcium 
increase remained practically unaltered (Figure 4A).  
Addition of 10 µM Bay k8644 to the medium increased significantly the 
response of activted BV2 cells to 80 mM KCl (Figure 4C-E). In the presence of 
Bay k8644, 78.8% of cells showed  a higher increase of [Ca2+]i due to KCl with a 
F340/F380 ratio of 0.351 ± 0.04, which corresponded to a 31.3%  increase from 
the base line (64 out of 81 cells from 3 different experiments; KW = 4.459, p = 
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0.032). Bay k8644 incubation also sligthly increased the Tpeack of the response 
63.1 ± 2.29 s (p< p.05), slightly increased the (Figure 4B). 
L-type VGCC blockade decreases the pro-inflammatory response but does 
not modify the phagocytic capacity of BV2 microglia  
To investigate the role of the L-type VGCC in the control of microglial pro-
inflammatory signal release, 24 hours after activation with LPS+IFNγ BV2 cells 
were incubated with either 10 µM nifedipine, 25 µM nimodipine, or 10 µM Bay 
k8644, and NO production and TNF-α concentration were determined 24 hours 
later (Figure 5). Compared with control BV2 microglia, incubation with 
LPS+IFNγ increased NO (6-fold) and TNF-α (5-fold) production. Treatment of 
non-activated microglia with either nimodipine, nifedipine or bay k8644 did not 
significantly modified the extracellular concentrations of nitrite and TNF- α 
(Figure 5A-F). Treatment of activated BV2 microglia with 10 µM nifedipine 
during 24 hours significantly decreased the extracellular concentrations of nitrite 
(40% decrease, F2,12 = 13.39, p = 0.0009) and TNF-α (44% decrease, F2,6 = 
7.11, p = 0.0261) (Figure 5A,B). Incubation with 25 µM nimodipine gave similar 
results with a drastic 75% decrease of nitrite production (F2,12 = 9.511, p = 
0.039) and a 51% decrease in TNF-α (F2,12 = 14.27, p = 0.0003) (Figure 5C,D). 
10 µM Bay k8644 did not significantly modified the extracellular concentrations 
of nitrite and TNF-α (Figure 5E,F).  
Although the same stimulus can trigger microglial secretion of inflammatory 
signals and activation of phagocytosis, it has been proposed that they are 
regulated by different intracellular pathways (Kettenmann et al., 2011). In view 
of this we also investigated the role of the L-type VGCC in the control of 
phagocytic capacity of BV2 microglia (Figure 6A-I). The analysis was performed 
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48 hours after activation with LPS+IFNγ and 30 min after fluorosphere 
incubation. Activation of BV2 microglia with LPS+IFNγ increased the 
percentage of cells presenting FluoroSpheres in the cytoplasm (F2,33 = 402.19, p 
= 0.00001) as well as the number of FluoroSpheres within the cells (F2,33 = 7.41, 
p = 0.0022). Treatment with 10 µM nifedipine had no effect on this phagocytic 
capacity (Figure 6J-K). 
 
Discussion 
Here we demonstrate the expression of α1 subunits of L-Type VGCC in reactive 
microglia during excitotoxicity in the rat hippocampus and in cultured BV2 cells, 
in which nifedipine blocks the K+-induced [Ca2+]i elevation and inhibits the pro-
inflammatory activity of reactive microglia, and Bay k8644 enhances [Ca2+]i 
elevation. Evidence for microglial VGCC currents is limited to a single report, in 
which voltage-clamp experiments revealed a small inward Ca2+ current in 30% 
of the cells tested (Colton et al., 1994). Additional indirect evidence showed that 
treatment of cultured rat microglial cells with high K+ solutions enhanced 
superoxide anion production induced by phorbol 12-myristate 13-acetate, an 
effect that was blocked by nifedipine (Colton et al., 1994). These 
pharmacological observations are consistent with our in vivo and in vitro results, 
which provide direct molecular evidence of functional L-type VGCC expression 
by reactive BV2 microglia. Thus, the L-type VGCC emerges as a new player in 
the calcium-mediated signaling in microglia.  
The elevation of baseline [Ca2+]i is a central element in the regulation of certain 
executive functions in activated microglia (Kettenmann et al., 2011). In vitro 
microglial activation with LPS leads to a chronic elevation of [Ca2+]i in microglial 
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cells and a suppression of evoked calcium signaling (Hoffmann et al., 2003). 
Lowering the intracellular calcium with BAPTA restored much of the signaling 
efficacy. BAPTA also strongly attenuated the LPS-induced release of NO, TNF-
α, IL-6, IL-12, and other chemokines (Färber and Kettenmann, 2006). 
Furthermore, when isolated from Alzheimer’s brain patients in the vicinity of 
amyloid plaques and compared with controls, reactive microglia had a higher 
resting calcium level and reduced response amplitude to ATP (McLarnon, 
2005). Some evidence indicates that L-type VGCC may account for some of 
these [Ca2+]i changes. For instance, amyloid-beta peptides are able to induce in 
vitro microglial activation and elicit an increase in [Ca2+]i levels which are 
abolished by specific L-type VGCC blockers such as verapamil, nifedipine and 
diltiazem (Silei et al., 1999). Moreover, other calcium entry pathways are likely 
to be important in the regulation of microglial activity. For instance, a role for N-
type VGCC has been proposed in the pathogenesis of experimental 
autoimmune encephalomyelitis by regulating the microglial production of the 
monocyte chemoattractant protein-1 (Tokuhara et al., 2010).  
Microglia respond to damage by up-regulating functions that involve calcium 
signaling, such as proliferation, migration, phagocytosis and production of pro-
inflammatory cytokines, chemokines and trophic factors (Färber and 
Kettenmann, 2006). The up-regulation of the L-type VGCC in microglia may, 
therefore, have different pathophysiological implications. The effects of 
nifedipine and nimodipine on the secretion of NO and TNF-α by BV2 microglia 
evidence a role of this channel in microglial synthesis and the release of pro-
inflammatory substances. The discrete effects of Bay k8644 on the secretion of 
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NO and TNF-α by non-stimulated microglia suggest the L-type VGCC is not 
sufficient to induce such release and it has a modulatory role.  
The anti-inflammatory effect of L-type VGCC blockade appears to be specific, 
since phagocytosis could not be modulated by nifedipine. In mixed cultures, L-
type VGCC blockers such as nimodipine inhibit NO production and TNF-α, IL-
1β and prostaglandin E2 secretion from LPS-stimulated microglia accompanied 
and reduced the degeneration of dopaminergic neurons (Li et al., 2009). 
However, other functional implications of the L-type VGCC should not be ruled 
out. For example, the expression of this channel may not be a consequence of 
cell activation but an essential step in the phenotypic transition into the 
activated microglia state. Also, certain results suggest a role for the L-type 
VGCC in the control of proliferation and migration of activated microglia. For 
example, CCL5, a β-chemokine involved in immune responses including 
migration (Maghazachi, 2000), secretion (Logan et al., 2003) , and gene 
expression (Crabtree and Olson, 2002), specifically activates a nimodipine-
sensitive calcium current in microglia (Shideman et al., 2006). 
The vulnerability of the CNS to excitotoxic insults and hypoxia-ischemia differs 
according to brain areas (Rodríguez et al., 2009b). The microglial expression of 
the L-type VGCC described here may contribute to explaining this differential 
vulnerability. In pathological processes, microglia show a hybrid activation state 
that includes inflammatory actions and also characteristics of neuroprotection 
and repair (Graeber and Streit, 2010). Whether microglia adopt a phenotype 
that mostly exacerbates tissue injury or promotes brain repair probably depends 
on the diversity of signals from the lesion environment. Similarly, the expression 
level of calcium channels in microglia seems to be regulated by 
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microenvironmental factors and depends on the functional state of the cell 
(Kettenmann et al., 2011). Consequently, the expression of the L-type VGCC in 
activated microglia may be central in determining, at least in part, their 
participation in the pathogenic process. Inside this framework, dihydropyridine 
drugs such as nifedipine and nimodipine have neuroprotective properties 
(Schurr, 2004), although until now this property has not been ascribed to anti-
inflammatory effects. Thus, examining the potential immunomodulatory 
properties of these drugs might help to clarify the controversial effectiveness of 
calcium channel antagonists in experimental and clinical assays.  
Conclusion 
To sum up, our results provide clear evidence of the expression of α1 subunits 
of the L-type VGCC in reactive microglia during excitotoxicity in the rat 
hippocampus and in cultured BV2 cells. We also provide evidence of a role of 
the L-type VGCC in the control of the pro-inflammatory activity of reactive 
microglia. Taken together, these results suggest a leading role for the L-type 
VGCC in the control of microglial secretory activity during inflammatory 
processes of the CNS. Further experiments are needed to clarify the specific 
molecular mechanisms activated by this channel and its role on the prevention 
of neuronal cell loss induced by proinflammatory microglial activity. Their 
characterization would help to ascertain other putative functional implications of 
the L-type VGCC in the control of microglial functions. 
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PBS: Phosphate buffer saline; SEM: Standard error of the mean; TNF-α: Tumor 
necrosis factor alpha. 
Competing interests 
The authors declare that they have no conflict of interest. 
Author’s contributions  
NM & MJR got financial support for the study. JFE-P & MJR designed the study. 
MM-M, JFE-P & XG performed the experiments. JFE-P, MM-M, XG, NM & MJR 
analyzed and discussed the results. MM-M, NM & MJR wrote the manuscript  
Acknowledgements 
This research was supported by grants IPT- 2011-1091-900000 and IPT-2012-
0614-010000 from the Ministerio de Economia, and by grant 2014SGR1115 
from the Generalitat de Catalunya, Spain.  
References 
	  Ashcroft FM, Proks P, Smith PA, Ammälä C, Bokvist K, Rorsman P. 1994. 
Stimulus-secretion coupling in pancreatic beta cells. J Cell Biochem 55 
Suppl:54–65. 
Bading H, Ginty DD, Greenberg ME. 1993. Regulation of gene expression in 
hippocampal neurons by distinct calcium signaling pathways. Science 
260:181–186. 
Bataller R, Gasull X, Ginès P, Hellemans K, Görbig MN, Nicolás JM, Sancho-
Bru P, De Las Heras D, Gual A, Geerts A, Arroyo V, Rodés J. 2001. In vitro 
and in vivo activation of rat hepatic stellate cells results in de novo 
expression of L-type voltage-operated calcium channels. Hepatology  
33:956–962. 
26	  
Bean BP. 1989. Neurotransmitter inhibition of neuronal calcium currents by 
changes in channel voltage dependence. Nature 340:153–156. 
Berg M, Bruhn T, Frandsen A, Schousboe A, Diemer NH. 1995. Kainic acid-
induced seizures and brain damage in the rat: role of calcium homeostasis. J. 
Neurosci Res 40:641–646. 
Bernal F, Petegnief V, Rodríguez MJ, Ursu G, Pugliese M, Mahy N. 2009. 
Nimodipine inhibits TMB-8 potentiation of AMPA-induced hippocampal 
neurodegeneration. J Neurosci Res 87:1240–1249. 
Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. 2005. International 
Union of Pharmacology. XLVIII. Nomenclature and structure-function 
relationships of voltage-gated calcium channels. Pharmacol Rev 57:411–425. 
Colton CA, Jia M, Li MX, Gilbert DL.1994.  K+ modulation of microglial 
superoxide production: involvement of voltage-gated Ca2+ channels. Am J 
Physiol 266:C1650–1655. 
Colton CA, Wilcock DM. 2010. Assessing activation states in microglia. CNS 
Neurol Disord Drug Targets 9:174–191. 
Crabtree GR, Olson EN. 2002. NFAT signaling: choreographing the social lives 
of cells. Cell 109 Suppl:S67–79. 
Damani MR, Zhao L, Fontainhas AM, Amaral J, Fariss RN, Wong WT. 2011. 
Age-related alterations in the dynamic behavior of microglia. Aging Cell 
10:263–276. 
Domercq M, Vázquez-Villoldo N, Matute C. 2013. Neurotransmitter signaling in 
the pathophysiology of microglia. Front Cell Neurosci 7:49. 
Färber K, Kettenmann H. 2006. Purinergic signaling and microglia. Pflugers 
Arch 452:615–621. 
Frandsen A, Schousboe A, Griffiths R. 1993. Cytotoxic actions and effects on 
intracellular Ca2+ and cGMP concentrations of sulphur-containing excitatory 
amino acids in cultured cerebral cortical neurons. J Neurosci Res 34:331–
339. 
Fryer HJ, Knox RJ, Strittmatter SM, Kalb RG. 1999. Excitotoxic death of a 
subset of embryonic rat motor neurons in vitro. J Neurochem 72:500–513. 
Graeber MB, Streit WJ. 2010. Microglia: biology and pathology. Acta 
Neuropathol 119:89–105. 
Hegg CC, Hu S, Peterson PK, Thayer SA. 2000. Beta-chemokines and human 
immunodeficiency virus type-1 proteins evoke intracellular calcium increases 
in human microglia. Neuroscience 98:191–199. 
Hoffmann A, Kann O, Ohlemeyer C, Hanisch U-K, Kettenmann H. 2003. 
Elevation of basal intracellular calcium as a central element in the activation 
27	  
of brain macrophages (microglia): suppression of receptor-evoked calcium 
signaling and control of release function. J Neurosci 23:4410–4419. 
Horn J, de Haan RJ, Vermeulen M, Limburg M. 2001. Very Early Nimodipine 
Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. 
Stroke 32:461–465. 
Jaskolski F, Mulle C, Manzoni OJ. 2005. An automated method to quantify and 
visualize colocalized fluorescent signals. J Neurosci Methods 146:42–49. 
Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A. 2011. Physiology of 
microglia. Physiol Rev 91:461–553. 
Li Y, Hu X, Liu Y, Bao Y, An L. 2009. Nimodipine protects dopaminergic 
neurons against inflammation-mediated degeneration through inhibition of 
microglial activation. Neuropharmacology 56:580–589. 
Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. 2012. Transformation from a 
neuroprotective to a neurotoxic microglial phenotype in a mouse model of 
ALS. Exp Neurol 237:147–152. 
Lipscombe D, Helton TD, Xu W. 2004. L-type calcium channels: the low down. J 
Neurophysiol 92:2633–2641. 
Logan MR, Odemuyiwa SO, Moqbel R. 2003. Understanding exocytosis in 
immune and inflammatory cells: the molecular basis of mediator secretion. J. 
Allergy Clin Immunol 111:923–932; quiz 933. 
Maghazachi AA. 2000. Intracellular signaling events at the leading edge of 
migrating cells. Int J Biochem Cell Biol 32:931–943. 
Manders EMM, Verbeek FJ, Aten JA. 1993. Measurement of co-localisation of 
objects in dual-colour confocal images. J Microscopy 169:375–382. 
Mattsson P, Aldskogius H, Svensson M. 1999. Nimodipine-induced improved 
survival rate of facial motor neurons following intracranial transection of the 
facial nerve in the adult rat. J Neurosurg 90:760–765. 
McLarnon JG. 2005. Purinergic mediated changes in Ca2+ mobilization and 
functional responses in microglia: effects of low levels of ATP. J Neurosci 
Res 81:349–356. 
Ortega FJ, Gimeno-Bayon J, Espinosa-Parrilla JF, Carrasco JL, Batlle M, 
Pugliese M, Mahy N, Rodríguez MJ. 2012a. ATP-dependent potassium 
channel blockade strengthens microglial neuroprotection after hypoxia-
ischemia in rats. Exp Neurol 235:282–296. 
Ortega FJ, Vidal-Taboada JM, Mahy N, and Rodríguez MJ. 2012b. Molecular 
mechanisms of acute brain injury and ensuing neurodegeneration. In A. 
González-Quevedo ed. Brain Damage - Bridging between basic research 
and clinics. Rijeka InTech, pp. 163-186. 
28	  
Ortega FJ, Jolkkonen J, Mahy N, Rodríguez MJ. 2013. Glibenclamide enhances 
neurogenesis and improves long-term functional recovery after transient focal 
cerebral ischemia. J Cereb Blood Flow Metab 33: 356-364. 
Paxinos G and Watson J. 1986. The rat brain in stereotaxic coordinates. 
Academic Press. 
Petegnief V, Ursu G, Bernal F, Mahy N. 2004. Nimodipine and TMB-8 
potentiate the AMPA-induced lesion in the basal ganglia. Neurochem Int 
44:287–291. 
Rami A, Krieglstein J. 1994. Neuronal protective effects of calcium antagonists 
in cerebral ischemia. Life Sci 55:2105–2113. 
Rodríguez MJ, Ursu G, Bernal F, Cusí V, Mahy N. 2001. Perinatal human 
hypoxia-ischemia vulnerability correlates with brain calcification. Neurobiol. 
Dis 8:59–68. 
Rodríguez MJ, Prats A, Malpesa Y, Andrés N, Pugliese M, Batlle M, Mahy N. 
2009a. Pattern of injury with a graded excitotoxic insult and ensuing chronic 
medial septal damage in the rat brain. J Neurotrauma 26:1823–1834. 
Rodríguez MJ, Pugliese M, and Mahy N. 2009b. Drug abuse, brain calcification 
and glutamate-induced neurodegeneration. Curr Drug Abuse Rev 2:99-112. 
Rodríguez MJ, Martinez-Moreno M, Ortega FJ, Mahy N. 2013. Targeting 
microglial KATP channels to treat neurodegenerative diseases: a 
mitochondrial issue. Oxid Med Cell Long 2013:194546. 
Schurr A. 2004. Neuroprotection against ischemic/hypoxic brain damage: 
blockers of ionotropic glutamate receptor and voltage sensitive calcium 
channels. Curr Drug Targets 5:603–618. 
Shideman CR, Hu S, Peterson PK, Thayer SA. 2006. CCL5 evokes calcium 
signals in microglia through a kinase-, phosphoinositide-, and nucleotide-
dependent mechanism. J Neurosci Res 83:1471–1484. 
Silei V, Fabrizi C, Venturini G, Salmona M, Bugiani O, Tagliavini F, Lauro GM. 
1999. Activation of microglial cells by PrP and beta-amyloid fragments raises 
intracellular calcium through L-type voltage sensitive calcium channels. Brain 
Res 818:168–170. 
Small DL, Monette R, Buchan AM, Morley P. 1997. Identification of calcium 
channels involved in neuronal injury in rat hippocampal slices subjected to 
oxygen and glucose deprivation. Brain Res. 753:209–218. 
Soto D, Comes N, Ferrer E, Morales M, Escalada A, Palés J, Solsona C, Gual 
A, Gasull X. 2004. Modulation of aqueous humor outflow by ionic 
mechanisms involved in trabecular meshwork cell volume regulation. Invest 
Ophthalmol Vis Sci 45:3650–3661. 
Strober W. 2001. Trypan blue exclusion test of cell viability. Curr Protoc 
29	  
Immunol Appendix 3:Appendix 3B. 
Toba Y, Pakiam JG, Wray S. 2005. Voltage-gated calcium channels in 
developing GnRH-1 neuronal system in the mouse. Eur J Neurosci 22:79–92. 
Tokuhara N, Namiki K, Uesugi M, Miyamoto C, Ohgoh M, Ido K, Yoshinaga T, 
Yamauchi T, Kuromitsu J, Kimura S, Miyamoto N, Kasuya Y. 2010. N-type 
calcium channel in the pathogenesis of experimental autoimmune 
encephalomyelitis. J Biol Chem 285:33294–33306. 
Virgili N, Espinosa-Parrilla JF, Mancera P, Pastén-Zamorano A, Gimeno-Bayon 
J, Rodríguez MJ, Mahy N, Pugliese M. 2011. Oral administration of the KATP 
channel opener diazoxide ameliorates disease progression in a murine 
model of multiple sclerosis. J Neuroinflamm 8:149. 
Virgili N, Mancera P, Chanvillard C, Wegner A, Wappenhans B, Rodríguez MJ, 
Infante-Duarte C, Espinosa-Parrilla JF, Pugliese M. 2014. Diazoxide 
attenuates autoimmune encephalomyelitis and modulates lymphocyte 
proliferation and dendritic cell functionality. J Neuroimm Pharmacol 9:558–
568. 
Zamponi GW, Snutch TP. 2013. Advances in voltage-gated calcium channel 
structure, function and physiology. Biochim Biophys Acta 1828:1521. 
Zhang H, Wang FW, Yao LL, Hao AJ. 2011. Microglia--friend or foe. Front 
Biosci. (Schol Ed) 3:869–883. 
Zhu D, Li R, Liu G, Hua W. 1999. Nimodipine inhibits calcium-independent nitric 
oxide synthase activity in transient focal cerebral ischemia rats and cultured 
mouse astroglial cells. Life Sci 65:PL221–231. 
30	  
FIGURE LEGENDS 
Figure 1. Effects of NMDA injection and immunodetection of α1C subunit in 
the rat hippocampus. Illustrative microphotographs of cresyl-violet stained 
hippocampal sections of sham (A) and NMDA lesioned rats (B) showing the 
hippocampal layer disorganization, neuronal loss, and glial reaction 15 days 
after NMDA injection. NeuN immunostaining of the hippocampus of sham (C) 
and NMDA rats (D) shows the neuronal loss as an area of devoid of 
immunoreactivity. Insets in C-D illustrate the morphology of stained pyramidal 
neurons inside the square in sham and NMDA lesioned rats. IB4 staining of the 
hippocampus of sham (E) and NMDA rats (F) as an estimation of the microglial 
reaction to NMDA injection. Insets in E-F illustrate the morphology of stained 
cells inside the square in sham and NMDA lesioned rats. Graphs show the 
quantification of: (G) the area of lesion measured on Nissl stained sections, (H) 
the percent of neuronal loss in the pyramidal stratum of Cornu Ammonis 1 
measured in NeuN-immunostaimed sections and (I) thearea of microglia 
reaction measured on IB4 stained hippocampal sections. (J) Specific neuronal 
α1C-immunoreactivity was observed in sham rats, with clear staining in neuronal 
processes of the pyramidal (J1) and radiatum (J2) strata of Cornu Ammonis 1. 
(K) NMDA induced disorganization of pyramidal stratum of Cornu Ammonis 1 
was evidenced by α1C immunostaining (K1). A non-neuronal specific anti-rat α1C 
immunostaining was also observed in NMDA-lesioned hippocampus, which was 
evident in the radiatum (K2) stratum of Cornu Ammonis 1. PyrCA1, pyramidal 
stratum of Cornu Ammonis; DG, dentate gyrus. Arrows in A-F indicate the 
injection site. Scale bar 1 mm; insets, K1 and K2, 50 µm. 
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Figure 2. Expression of α1C in activated IB4-positive cells in the 
hippocampus of NMDA ,Klesioned rats. (A-C, J) Stack images of double 
immunohistochemistry of α1C (green) and IB4 (red) in the hippocampus of sham 
animals. (D-F, K) Stack images of double immunohistochemistry of α1C and IB4 
in the hippocampus of NMDA-lesioned rats with some IB4-positive cells also 
positive for α1C (white arrows). Confocal analysis of the image of a XY plane (G) 
with the merged channels, the MDP map of the image (H), and the scatter plot 
(I). The presence of yellow dots in G, H and I denotes the presence of IB4 and 
α1C colocalization for both channels, in which IB4-postive cells of the lesioned 
hippocampus express α1C. Colocalization parameters from (I) are Pearson’s r = 
0.413, Overlap coefficient = 0.685, Overlap coeficient for green (k1) = 0.739 and 
for red (k2) = 0.635. Scale bar 40 µm for A-F; 100 µm for G-H, 10 µm for J, K. 
Figure 3. Expression of the L-type VGCC in BV2 microglia. Murine BV2 cell 
culture was analyzed 48h after activation with LPS+IFNγ (see material and 
methods for details). RT-PCR analyses of L-Type VGCC subunits were 
performed with gene-specific primers. PCR products for α1D (A) and (B) α1C 
subunits (arrows) were separated by 1.5% agarose gel electrophoresis and 
stained with ethidium bromide. Each gel was loaded with standard size markers 
(line 1) and cDNA amplified from brain as control (brain); c, non-activated BV2 
cells; L+I, BV2 cells activated with LPS+IFNγ; Hek, total RNA from HEK293 
cells (used as negative PCR control). Amplified fragments had the sizes of 226 
bp for α1D and 223 bp for α1C, as predicted by the mRNA sequence amplicons 
(n= 3 different cultures). (C) Immunoblot and densitometry quantification of α1C 
expressed by control (c) and activated (L+I) BV2 cells. Homogenates were 
normalized for protein content quantified by Bradford’s method, 15 mg of protein 
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was applied in each gel lane and each sample was loaded into two lanes. 
Bands appeared at the level of 240 kDa; for quantification, β-Actin immunoblott 
was used as loading control (n= 5 different cultures) (D-F): 
Immunocytochemistry with specific antibodies against α1C was performed in 
control (E) and BV2 cells activated with LPS+IFNγ (F) Specificty of the antibody 
was assessed in control cells by immunodetection in absence of primary 
antibody (D). Specific binding (arrowheads in F) was detected with AlexaFluor 
488-conjugated secondary antibodies (green). Note that activated BV2 cells are 
larger and showed numerous processes, as published elsewhere (Ortega et al., 
2012a; see also Figure 5). (n= 3 different cultures). Scale Bar 20 µm.  
Figure 4. Effects of pharmacological modulation of the L-type VGCC on 
intracellular calcium permeability of BV2 microglia. (A-B) Illustrative 
representation of [Ca2+]i kinetics in one single activated BV-2 cell before and 
after 2 min depolarization with 80 mM KCl (black bar). (A) Addition in the bath of 
10 µM nifedipine for 3 min (Nif, gray bar) significantly reduced the increase of 
[Ca2+]i induced by KCl (dashed line vs continuous line). (B) Addition in the bath 
of 10 µM Bayk for 3 min (gray bar) significantly enhanced the increase of [Ca2+]i 
induced by KCl. (dashed line vs continuous line) (C) Histogram showing the 
340- to 380-nm fluorescence ratios as an estimation of the [Ca2+]i changes 
induced by 80 mM KCl addition in control and LPS+IFNγ activated BV2 cells 
(L+I) loaded with Fura-2. Effects of L-type VGCC on [Ca2+]i changes were 
assessed by addition of either 10 µM Nifedipine (Nif) or 10 µM Bay k8644 
(Bayk). n = 154 cells in control (70 for KCl, 46 for KCl+Nif –both from 7 different 
experiments- and 38 for KCl+Bayk -from 3 different experiments-) and n = 280 
cells in L+I (151 cells for KCl, 83 cells for KCl+Nif –both from 7 different 
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cultures- and 46 cells for KCl+Bayk –from 3 different cultures-) (D) Histogram 
shows the percent of cells responding to 80 mM KCl in control and L+I activated 
cells in all six conditions. (E) Histogram shows the percent of [Ca2+]i changes 
induced by 80 mM KCl found in the responsive cells in the six conditions 
studied. * p<0,05 compared with KCl control, # p < 0.05 compared with KCl L+I 
(Mann-Whitney test). Values are presented as mean ±SEM 
Figure 5. Effects of pharmacological modulation of the L-type VGCC on 
the pro-inflammatory response of BV2 microglia. Histograms show TNF-α 
release and NO production of control and LPS+IFNγ activated (L+I) BV2 cells 
assessed 48h after activation, and post-treated with either (A,B) 10 µM 
nifedipine (Nif, n = 7 different cultures), (C,D) 25 µM nimodipine (Nim, n = 3 
different cultures) or (E,F) 10 µM Bay k8644 (BayK, n = 3 different cultures) for 
24 hours. NO production was quantified by the Griess method and TNF-α 
release was quantified by ELISA * p<0,05 compared with control, # p < 0.05 
compared with L+I (Mann-Whitney test). Values are presented as mean ± SEM  
Figure 6. Nifedipine does not modify the phagocytic activity of reactive 
BV2 microglia. The phagocytic capacity of BV2 cells was assessed 48h after 
activation with LPS+IFNγ and post-treated with 10 µM Nifedipine, (A-J) 
Illustrative microphotographs of the effects of nifedipine on the phagocytosis of 
FluoroSpheres (red) by BV2 microglia (green). Graphs show the quantification 
of the BV2-cell phagocytic capacity measured using the FluoroSpheres assay 
(see material and method for details). The estimated phagocytic parameters 
were the number of spheres per cell (K) and the percentage of phagocytic cells 
(L). (n = 4 cultures, * p < 0.05 compared with Control, LSD posthoc). Scale bar: 
10 µm. 
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Figure 1: Effects of NMDA injection and immunodetection of α1C subunit in the rat 
hippocampus 
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Figure 2: Expression of α1C in activated IB4-positive cells in the hippocampus of 
NMDA-lesioned rats. 
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Figure 3: Expression of the L-type VGCC in BV2 microglia. 
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Figure 4: Effects of pharmacological modulation of the L-type VGCC on intracellular 
calcium permeability of BV2 microglia. 
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Figure 5: Effects of pharmacological modulation of the L-type VGCC on the pro-
inflammatory response of BV2 microglia. 
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Figure 6: Nifedipine does not modify the phagocytic activity of reactive BV2 microglia. 
 
 
